Dr. Jesus Gomez, M.D.
What this data tells you about Dr. Gomez
Dr. Jesus Gomez is an optician in El Paso, TX, with 20 years in practice. Based on federal Medicare data, Dr. Gomez performed 77,239 Medicare services across 2,171 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gomez received a total of $336 from 10 pharmaceutical and/or device companies across 12 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gomez is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 19,000 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) | 16,950 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 13,000 | $0 | $33 |
| Darbepoetin injection (Aranesp) for anemia | 7,490 | $2 | $20 |
| Denosumab injection (Prolia/Xgeva) | 3,660 | $18 | $66 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,290 | $22 | $181 |
| Dexamethasone injection (steroid) | 2,230 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,480 | $1 | $114 |
| Contrast dye for imaging (iodine-based) | 1,219 | $0 | $3 |
| Injection, granisetron hydrochloride, 100 mcg | 950 | $0 | $24 |
| Office visit, established patient (30-39 min) | 886 | $87 | $368 |
| Blood draw (venipuncture) | 817 | $8 | $20 |
| Complete blood count (CBC) with differential | 752 | $8 | $36 |
| Comprehensive metabolic blood panel | 703 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 701 | $2 | $13 |
| Injection of additional new drug or substance into vein | 670 | $12 | $108 |
| Injection, leucovorin calcium, per 50 mg | 634 | $3 | $25 |
| Injection, fulvestrant, 25 mg | 620 | $8 | $244 |
| Administration of chemotherapy into vein, 1 hour or less | 459 | $97 | $707 |
| Injection, carboplatin, 50 mg | 225 | $2 | $300 |
| Drug injection, under skin or into muscle | 217 | $10 | $96 |
| Injection, zoledronic acid, 1 mg | 202 | $6 | $431 |
| Administration of chemotherapy into vein, each additional hour | 192 | $21 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 176 | $22 | $157 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 151 | $53 | $211 |
| Administration of additional new drug or substance into vein, 1 hour or less | 140 | $48 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 111 | $1 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 107 | $24 | $145 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 103 | $132 | $3,675 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 92 | $272 | $2,762 |
| Irrigation of implanted venous access drug delivery device | 91 | $16 | $114 |
| Administration of additional new drug or substance into vein using push technique | 84 | $42 | $289 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 71 | $124 | $500 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 67 | $45 | $313 |
| Lactate dehydrogenase (enzyme) level | 65 | $6 | $31 |
| Carcinoembryonic antigen (cea) protein level | 60 | $19 | $99 |
| Microscopic examination for white blood cells with manual cell count | 47 | $4 | $22 |
| Complete blood count (CBC), automated | 47 | $6 | $34 |
| Infusion into a vein for hydration, each additional hour | 45 | $10 | $75 |
| Infusion, normal saline solution , 1000 cc | 45 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 41 | $15 | $94 |
| Reticulated (young) platelet measurement | 39 | $35 | $143 |
| Hospital follow-up visit, high complexity | 38 | $88 | $357 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 38 | $90 | $657 |
| Iron level test | 37 | $6 | $27 |
| Iron binding capacity test | 37 | $9 | $35 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 35 | $1,108 | $4,802 |
| Injection of drug or substance into vein | 32 | $27 | $247 |
| Unclassified drugs | 32 | $1 | $8 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 20 | $1 | $17 |
| New patient office visit (45-59 min) | 18 | $111 | $565 |
| Ct scan of chest with contrast | 12 | $48 | $821 |
| CT scan of abdomen and pelvis with contrast | 11 | $175 | $1,067 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (50%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in optician and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
3.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Gomez is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and speaking/promotional industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Gomez experienced with pembrolizumab injection (keytruda)?
Does Dr. Gomez receive payments from pharmaceutical companies?
How do Dr. Gomez's costs compare to other opticians in El Paso?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology